IgA nephropathy secondary prevention

IgA nephropathy Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating IgA nephropathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
IgA nephropathy secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of IgA nephropathy secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on IgA nephropathy secondary prevention
CDC on IgA nephropathy secondary prevention
IgA nephropathy secondary prevention in the news
Blogs on IgA nephropathy secondary prevention
Directions to Hospitals Treating IgA nephropathy
Risk calculators and risk factors for IgA nephropathy secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2]

Overview

There are no established measures for the secondary prevention of IgA nephropathy.

Secondary Prevention

• There are no established measures for the secondary prevention of IgA nephropathy.